β(2) -adrenoceptor agonists: current and future direction.

@article{Cazzola20112A,
  title={β(2) -adrenoceptor agonists: current and future direction.},
  author={Mario Cazzola and Luigino Calzetta and Maria Gabriella Matera},
  journal={British journal of pharmacology},
  year={2011},
  volume={163 1},
  pages={4-17}
}
Despite the passionate debate over the use of β(2) -adrenoceptor agonists in the treatment of airway disorders, these agents are still central in the symptomatic management of asthma and COPD. A variety of β(2) -adrenoceptor agonists with long half-lives, also called ultra long-acting β(2) -adrenoceptor agonists (ultra-LABAs; indacaterol, olodaterol, vilanterol, carmoterol, LAS100977 and PF-610355) are currently under development with the hopes of achieving once-daily dosing. It is likely that… CONTINUE READING